FDA approves Targiniq ER with abuse-deterrent properties

[7/23/2014] FDA has approved Targiniq ER, a new extended-release pain reliever that contains a combination of oxycodone and naloxone. Targiniq ER is the second extended-release/long-acting (ER/LA) opioid analgesic with FDA-approved labeling describing the product’s properties that are expected to reduce, but not totally prevent, abuse by snorting or injecting.  

July 23, 2014

Related Information


Page Last Updated: 10/29/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English